https://www.facebook.com/103190785608480/

Abdelrahman Azzam, Cairo (2026)

15/08/2025

New ACC guidelines for management of hypertension
Just released today
Link in comments

11/07/2025

ليه البراسوجريل بيفضل عن البلافيكس مع انه الاكثر انتشارا والاكثر استخداما
ده بيرجع لـ٣ عوامل مهمة
▪ rapid onset of action
▪ more potent inhibitor of P2Y receptors
▪ its metabolism isn‘t influenced by cytochrome P450

وده اللي تم اثباته في دراسة TRITON-TIMI 38
(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in
Myocardial Infarction)
التي قارنت بين عقار بْراسوجريل وعقار كْلوبيدوجريل في مجوعة من مرضى
moderate to severe ACS
والذين يخضعون لعملية قسطرة قلبية (percutaneous coronary intervention or PCI).
In TRITON-TIMI 38, patients with moderate to high-risk ACS 74% NSTEACS undergoing PCI treated with a P2Y12 inhibitor x 14.5
months:
the primary end point was a composite of death due to cardiovascular causes, nonfatal MI, or nonfatal stroke. Patients who received prasugrel had a significant reduction in the primary end point compared with patients who received clopidogrel (9.9% vs. 12.1%) hazard ratio

Address

Cairo

Telephone

+201060793332

Website

facebook.com

Alerts

Be the first to know and let us send you an email when Abdelrahman Azzam posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Abdelrahman Azzam:

Abdelrahman Azzam